Keyphrases
Pembrolizumab
100%
Phase II Study
41%
Phase II Clinical Trial
31%
Streptomyces Lividans
27%
Progression Rate
22%
Non-progression
22%
Long Amplicon
18%
Clinical Benefit Rate
18%
Adrenocortical Carcinoma
18%
Cancer Immunotherapy
18%
Tumor
17%
Basket Trial
16%
Rare Tumors
16%
Repertoire Sequencing
16%
Programmed Death-ligand 1 (PD-L1)
15%
Tumor-infiltrating Lymphocytes
15%
Objective Response Rate
15%
Solid Tumors
15%
Confidence Interval
15%
Conjugative Transfer
13%
Metastatic Pheochromocytoma
13%
Recurrent Granulosa Cell Tumor
13%
KCNQ2 Encephalopathy
13%
Kv7.2
13%
Kinesin Motors
13%
Conventional Kinesin
13%
KCNQ2
13%
Gene Polymorphism
13%
Clinical Efficacy
13%
T Cell Receptor
13%
Lower Genital Tract
13%
Protein Kinase CK2
13%
Interneuronopathy
13%
Clinical Safety
13%
Response-outcome
13%
M-current
13%
Kinase Protein
13%
Linear Mode
13%
Immune-related Adverse Events
13%
Treatment Outcome
13%
Anti-PD-1
13%
Small Cell Neuroendocrine Carcinoma
13%
Advanced Adrenocortical Carcinoma
13%
Apramycin
13%
Rare Cancer
13%
Diagnostic Procedures
13%
Linear Plasmid
13%
M-channel
13%
Anchoring Proteins
13%
Protein Phosphatase
13%
Biochemistry, Genetics and Molecular Biology
Axon
48%
Ankyrin
41%
Kinesin
27%
Casein Kinase 2
27%
Streptomyces lividans
27%
T Cell Receptor
27%
Calmodulin
27%
Electric Potential
20%
Haplotype
19%
Amplicon
19%
Sodium Channel
18%
N-Terminus
18%
Potassium Channel
17%
Secretion (Process)
15%
Immunity
14%
Leptin
13%
M Current
13%
Plasmid
13%
Node of Ranvier
13%
Genetic Structure
13%
Isoform
13%
Protein Phosphatase 1
13%
Cancer Immunotherapy
13%
Homeostasis
13%
Antiporter
13%
Spectrin
13%
Essential Gene
13%
Gene Polymorphism
13%
Voltage-Gated Potassium Channel
13%
Cyclic Adenosine Monophosphate
13%
Action Potential
12%
Excitability
11%
Cell Membrane
11%
KIF5B
11%
Allele
10%
C-Terminus
9%
Wild Type
9%
Voltage-Gated Channel
7%
Gene Linkage
6%
Current Density
6%
Locomotion
6%
Missense
6%
Episodic Ataxia
6%
Binding Site
6%
Axolemma
6%
Next Generation Sequencing
5%
Channel Protein
5%
Energy Balance
5%
Glucose Homeostasis
5%
Knockout Mouse
5%
Medicine and Dentistry
Pembrolizumab
96%
Neoplasm
53%
Clinical Trial
34%
Adverse Event
28%
Biopsy Technique
27%
Diseases
26%
Cancer
23%
Paraganglioma
20%
Adrenal Cortex Carcinoma
20%
Pheochromocytoma
20%
Rare Tumor
16%
Exon
13%
Leptin
13%
Bipolar Disorder
13%
Secretion (Process)
13%
Cyclic AMP
13%
Tumor Biopsy
13%
Antiporter
13%
White Adipose Tissue
13%
Homeostasis
13%
Ankyrin
13%
Granulosa Cell Tumour
13%
Neuroendocrine Carcinoma
13%
Pituitary Cancer
13%
Progression Free Survival
11%
Immunotherapy
10%
Interneuron
7%
Systemic Therapy
7%
Primary Tumor
6%
Cancer of Unknown Primary Origin
6%
Inflammatory Cell
6%
Squamous Cell Carcinoma
6%
Programmed Cell Death
6%
Immunity
6%
Temozolomide
5%
Parvalbumin
5%
Adipose Tissue
5%
Energy Balance
5%
Next Generation Sequencing
5%
Tumor Microenvironment
5%
Glucose Homeostasis
5%
Neuroendocrine Tumor
5%
Diet Induced Obesity
5%
Disease Exacerbation
5%
Patient Population
5%